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$1954 for MS patients. CONCLUSIONS: Adding fenoﬁbrate to
statin therapy in diabetes and MS increases the number of
patients achieving lipid targets at a relatively small incremental
cost.
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OBJECTIVES: Treating patients to target has been shown to
delay complications of type 2 diabetes mellitus (T2DM). We
developed a model to explore the effectiveness of oral agents in
achieving target levels for HbA1c and lipids in patients with
T2DM. METHODS: The model is broad enough to cover most
relevant comparisons. One analysis considered patients with
T2DM and moderate dyslipidaemia: Triglycerides (TG) of 2.66
+/- 1.77mmol/l and High Density Lipoprotein Cholesterol
(HDL-C) of 1.09 +/- 0.26mmol/l, who had failed
metformin/sulphonylurea therapy. Following UK guidelines,
patients either received rosiglitazone plus a sulphonylurea
(Rosi+SU) or a hypothetical treatment that would simultane-
ously improve HDL, TG and HbA1c by 10%. Patients switched
to insulin if therapy was not tolerated or HbA1c targets not met.
The main outcome measure was Days at Target, deﬁned as the
number of days on which American Diabetic Association target
levels for HbA1c, TG and HDL-C were achieved. The time
horizon considered was 3 years, composed of six month cycles:
long-term diabetic complications were not included. RESULTS:
For Rosi+SU over one year, a cohort of 100 patients would spend
27,854 patient-days at HbA1c target, but only 5,808 patient-
days at combined HbA1c and lipid targets. The increase in Days
at Target per 100 patients treated was 136 for a 10% improve-
ment in TG; 192 for a 10% improvement in HDL; 228 for a
10% improvement in HbA1c, and 667 for improvement in all
three. The model was sensitive to the severity of dyslipidaemia
at baseline. CONCLUSION: The model suggests that existing
agents are more effective at achieving HbA1c control than reach-
ing target lipid levels. Improving HbA1c would provide the
single largest gain in Days at Target, but simultaneous improve-
ment in HbA1c and lipids would be needed to achieve a sub-
stantial gain in diabetes control.
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OBJECTIVES: To project comparative economic and clinical
outcomes associated with treating type 1 diabetes patients on
basal-bolus therapy with insulin glargine (IGlar) or detemir
(IDet), each combined with aspart (IAsp). METHODS: A pub-
lished, peer-reviewed and validated computer simulation model
of diabetes was used to project clinical and cost outcomes over
time horizons of 5, 10, 20, and 35 years. Treatment effect data
were derived from a multicenter, 26 week randomized controlled
trial among subjects with a mean age of 40.2 years and baseline
HbA1c of 8.84% (duration of diabetes: 16.7 years). Equivalent
reduction of HbA1c, the primary endpoint, was observed (NS)
and minor hypoglycemia was parallel (NS), though statistically
signiﬁcant improvements in nocturnal (32% lower; p = 0.046)
and major hypoglycemic episodes (72% lower, p = 0.047; 6.51
vs. 24.5 events per 100 patient years) favored IDet. Costs were
taken from published sources in the US and expressed in 2004
US dollars ($). Clinical and cost outcomes were discounted at
3% per annum. Sensitivity analyses on key input parameters
were performed. RESULTS: Treatment with IDet was associated
with improvements in life expectancy (0.002 to 0.08 years) and
quality-adjusted life expectancy (0.01 to 0.06 QALYs). Direct
medical costs from a US Medicare perspective (pharmacy plus
complication costs) were lower in the IDet group ($672 to
$5174), with the incremental value increasing as the time
horizon lengthened. One-way sensitivity analysis on pharmacy
costs (±15%), discount rate (0–6%), complication costs, and
duration of treatment effect on HbA1c (<5 years) support the
robustness of these ﬁndings. CONCLUSION: Clinical beneﬁts
associated with IDet + IAsp therapy compared to IGlar + IAsp
were projected to improve life expectancy, quality-adjusted life
expectancy and to reduce costs in patients with type 1 diabetes
over a time horizon of 5 to 35 years.
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OBJECTIVES: To provide an estimate of the clinical and eco-
nomic outcomes of long-term use of either all analog (insulin
detemir (IDet) + aspart (IAsp)) or all human (NPH + human
soluble insulin (HSI)) basal bolus regimens among type 1 dia-
betes patients. METHODS: Comparative efﬁcacy data was
obtained from a recent 18-week randomized controlled trial (n
= 595) which demonstrated statistically signiﬁcant beneﬁts in
glycemic control (HbA1c: -0.22%, p < 0.001; PPG excursions:
p < 0.001), risk for hypoglycemia (all: 21% lower, p = 0.036;
26.9 vs. 34.6 events per patient year; nocturnal: 55% lower, p <
0.001), and weight gain (-1.01kg, p < 0.001) in favor of analogs.
Subjects were 63% male, aged 39.1 years, and had a mean base-
line HbA1c of 8.38% (duration of diabetes: 15.3 (10.3) years).
A published, peer-reviewed and validated model of type 1 dia-
betes was used to make long-term projections, using second
order Monte Carlo methodology, to evaluate life expectancy,
quality-adjusted life expectancy, cumulative incidence of com-
plications, and direct medical costs (pharmacy plus complication
costs). Base case time horizon was 35 years. Future costs and
clinical beneﬁts were discounted at 3% annually. Sensitivity
analyses were performed. RESULTS: Treatment with IDet+IAsp
was projected to increase life expectancy (0.168 years), QALE
(0.698 QALYs), and reduce cumulative incidences of diabetes-
related comorbidities (cardiovascular, renal, and ocular disease)
versus NPH+HSI. Direct medical costs were higher in the
IDet+IAsp group, leading to an ICER of $14,974 per QALY
gained. One-way sensitivity analysis of pharmacy costs (±15%),
discount rate (0–6%), complication costs, and duration of 
treatment effect on HbA1c (<5 years) support the robustness of
these ﬁndings. CONCLUSION: Patients with type 1 diabetes
who require basal bolus therapy may beneﬁt from analog 
insulin treatment in comparison to human insulin. Long-term
therapy was projected to improve life expectancy, quality-
adjusted life expectancy, and complication rates, representing
good value for money according to commonly supported 
standards.
